by Shana Cristoferi | Sep 15, 2020 | Appili Therapeutics, News
Read original News Release HALIFAX, Nova Scotia, September 11, 2020 – Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has submitted a new...
by Shana Cristoferi | Jul 2, 2019 | Appili Therapeutics, News
Appili’s multi-drug resistant antibiotic program has the potential to address public health threats for both military and civilian populations worldwide. HALIFAX, Nova Scotia, July 2, 2019 – Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a...
by Shana Cristoferi | Jun 27, 2019 | Appili Therapeutics, IMV Inc., News, SONA NanoTech
Read full Entrevestor article here The stock market is looming larger in the Atlantic Canadian startup community than it ever has before, as several leading companies are choosing public markets as the best option to secure long-term financing. Just in the past week,...
by Shana Cristoferi | Jun 26, 2019 | Appili Therapeutics, NeuroQuest, News
See full Entrevestor article here Shares of Halifax drug discovery company Appili Therapeutics Inc. begin trading on the TSX Venture exchange today. The company, whose long-term goal is to produce drugs that can combat antibiotic-resistant viruses, issued...
by administrator | Oct 2, 2018 | Appili Therapeutics, News
Read the original article here. Appili Therapeutics, a Halifax-based drug development company, has appointed its first ever Chief Scientific Officer. Armand Balboni, the new CSO, will be responsible for the company’s clinical and scientific strategy as well as...
